Beijing Hanmi Drugs

Bio & Pharma Samsung Biologics to spin off biosimilar unit Samsung Bioepis

Samsung Biologics Co., the world’s largest contract drugmaker, will undergo a strategic split to separate its contract development and manufac...

Bio & Pharma Celltrion unveils cancer medicine to expand new drug pipelines

South Korea’s leading biosimilar drug developer Celltrion Inc. on Sunday unveiled an anticancer medicine to expand new pipelines and accelerat...

Economy China bans export of Korean goods containing its rare earth metals to US

The Chinese government has warned South Korean companies of retributions for exporting any product containing its critical metals to US military con...

Bio & Pharma Celltrion expands footprint in Latin America with flagship oncology drugs

South Korea’s biopharmaceutical giant Celltrion Inc. has solidified its presence in South America after winning supply contracts for its flags...

Shipping & Shipbuilding With domestic dockyards fully booked, Korean shipbuilders turn overseas

As order books swell amid green shipping mandates, LNG demand and military naval modernization, South Korean shipbuilders are extending their global...

Bio & Pharma Celltrion wins Australian approval for eye, bone disease biosimilars

Celltrion Inc. said Wednesday it has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for three biosimilar...

Business & Politics Samsung's Lee meets with Xi amid Beijing’s balancing act vs Washington

Samsung Electronics Co. Chairman Lee Jae-yong, along with other global tech leaders, met with Chinese President Xi Jinping in Beijing on Friday as C...

Bio & Pharma Celltrion to sell autoimmune drug Stelara biosimilar at Costco in US

South Korea’s leading biosimilar drug developer Celltrion Inc. said on Monday it is set to sell Steqeyma, a biosimilar to autoimmune disease t...

Bio & Pharma SillaJen: First to use lab-grown human tissue to find best cancer drug dose

South Korean biotechnology firm SillaJen Inc. is pioneering a new approach to determine the best dose for a cancer drug combination in clinical tria...

Bio & Pharma Chong Kun Dang to build new plant for foray into biologics market

Chong Kun Dang Pharmaceutical Corp. is discussing building a research center and a plant in Siheung, about 30 kilometers southwest of Seoul, with th...

Bio & Pharma Celltrion wins EU approval for autoimmune disease treatment Avtozma

Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European Commission, f...

Business & Politics China likely to lift ban on South Korea’s K-wave as early as May

BEIJING – China will likely lift its ban on Hallyu, or Korean popular culture in the country, as early as May, moving away from its “wol...

Electronics Hanmi Semiconductor to retire $90 mn treasury shares in May

Hanmi Semiconductor Co. on Thursday announced a plan to retire 130.0 billion won ($90 million) worth of treasury shares in May, marking its largest-...

Bio & Pharma Lotte Biologics eyes first ADC CDMO order in 2025

SAN FRANCISCO -- Lotte Biologics Co., the drug consignment development and production unit of South Korean conglomerate Lotte Group, will seek to wi...

IPOs Celltrion seeks large-scale M&A in Q4, eyes 2027 Nasdaq debut

SAN FRANCISCO – South Korea’s leading biosimilar drug developer Celltrion Inc. seeks to acquire a domestic health food maker as early as...

Bio & Pharma SK Biopharmaceuticals, Eurofarma to set up AI epilepsy platform JV in US

South Korea’s SK Biopharmaceuticals Co. has signed a deal with Brazil’s Eurofarma Laboratórios S.A. to establish a joint venture ...

Electronics Hanmi Semiconductor to build new TC Bonder plant in Incheon

Hanmi Semiconductor Co., South Korea’s leading chip packaging equipment manufacturer, held a ground-breaking ceremony for its seventh plant of...

Bio & Pharma Yuhan’s lung cancer drug gets OK in Europe

Leclaza (ingredient: lazertinib), a new lung cancer treatment developed by South Korea’s Yuhan Corp. secured approval from the European Commis...

Corporate governance Hanmi Pharm’s chair poised to win management feud with her son

Hanmi Pharmaceutical Group Chairman Song Young-sook is poised to claim victory in a year-long dispute with her eldest son Lim Jong-yoon to take cont...

Bio & Pharma Boryung, Lotus Pharma signs CDMO deal on anticancer injection

South Korea's Boryung Corp. said on Thursday it signed a contract with Lotus Pharmaceutical, a Taiwanese oncology firm, for contract development and...

Bio & Pharma Hanmi breaks ground pharmaceuticals complex in Beijing

South Korea's Hanmi Pharmaceutical Co. said on Friday that Beijing Hanmi Pharm, its subsidiary in China, held the groundbreaking ceremony for a proj...

Bio & Pharma SK Biopharm submits NDA of epilepsy drug to China

South Korea's SK Biopharmaceuticals Co. said on Tuesday it submitted the new drug application (NDA) for its flagship epilepsy drug Cenobamate to Chi...

Private equity La Defense might have a say over Hanmi Pharm's family feud

La Defense Partners is expected to exercise a casting vote over the ongoing management dispute at Hanmi Science Co. after the Seoul-based private eq...

Bio & Pharma Celltrion’s Remsima on course to become Korea’s 1st blockbuster drug

Celltrion Inc.'s Remsima, the world’s first biosimilar monoclonal antibody, is on track to exceed 1 trillion won ($713 million) in sales this ...

Bio & Pharma Hanmi Pharma to move up launch of anti-obesity drug

South Korea’s Hanmi Pharmaceutical Co. announced on Thursday the launch of its anti-obesity drug candidate efpeglenatide has been rescheduled ...

Bio & Pharma Samsung Biologics wins $668 million CDMO deal with European pharma

Samsung Biologics Co., the world’s largest contract drugmaker, said on Wednesday it has signed two drug manufacturing contracts worth a combin...

Banking & Finance Hanmi Bank rises from Koreatown lender to regional bank

It began in 1982 as a small community bank for Korean immigrants in Los Angeles, California. Today, Hanmi Bank, under Nasdaq-listed Hanmi Financial ...

Bio & Pharma Celltrion's anti cancer drugs hold 90% market share in C.America

South Korea’s Celltrion Inc. said on Friday that its cancer treatments have captured a 90% market share in several Central American countries....

Bio & Pharma Yuhan’s lung cancer drug clears FDA hurdle for global debut

A new lung cancer treatment developed by South Korea’s Yuhan Corp. has secured approval from the US Food and Drug Administration (FDA) as a co...

Pension funds NPS signals more say in Hanmi Pharmaceutical's family feud

South Korea’s National Pension Service is indicating more active involvement in the management of Hanmi Pharmaceutical Group embroiled in a ye...